Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

This study has been completed.
Information provided by (Responsible Party):
Luitpold Pharmaceuticals Identifier:
First received: October 21, 2005
Last updated: July 22, 2015
Last verified: July 2015
The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus carboplatin in a prospectively randomized trial. In addition, the response rate to each regimen, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.

Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: Taxoprexin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Luitpold Pharmaceuticals:

Primary Outcome Measures:
  • Overall survival after 380 deaths
    To compare the overall survival of patients with advanced NSCLC treated with either weekly Taxoprexin® in combination with carboplatin every 3 weeks or paclitaxel and carboplatin every 3 weeks. • To compare the safety and tolerability of weekly Taxoprexin® in combination with carboplatin every 3 weeks with paclitaxel and carboplatin administered every 3 weeks.

Secondary Outcome Measures:
  • Response rate
    To compare time to progression (TTP), time to treatment failure (TTF) and one-year survival in patients with advanced NSCLC treated with weekly Taxoprexin® in combination with carboplatin every 3 weeks or paclitaxel and carboplatin every 3 weeks. • To compare the objective response rates (ORR) and duration of response in patients with advanced NSCLC treated with either weekly Taxoprexin® in combination with carboplatin every 3 weeks or paclitaxel and carboplatin every 3 weeks. • Formal pharmacokinetics (PK) were to be done at selected sites for 18 patients randomized to treatment Arm A

Enrollment: 519
Study Start Date: November 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
(Taxoprexin® + carboplatin)
Drug: Taxoprexin
Experimental: Arm B
paclitaxel + carboplatin
Drug: Taxoprexin

Detailed Description:
This is a randomized, multicenter, Phase III open-label study of weekly Taxoprexin® in combination with every three (3) week carboplatin compared to paclitaxel plus carboplatin every three (3) weeks, in patients with advanced non-small cell lung cancer (NSCLC) who have not received cytotoxic agents for advanced disease. Patients may have been previously treated with immunological agents. Patients will be randomized to receive Taxoprexin® at a dose of 400 mg/m2 intravenously by one (1)-hour weekly infusion, 5/6 weeks followed immediately by carboplatin AUC = 4 on weeks one (1) and four (4) as a 30 minute intravenous infusion or paclitaxel 225mg/m2 as a three (3) hour intravenous infusion followed immediately by carboplatin AUC = 6 as a 30 minute intravenous infusion, every three (3) weeks. Patients will receive Taxoprexin® and carboplatin infusions or paclitaxel and carboplatin infusions until progression of disease, intolerable toxicity, completion of six (6) treatment cycles of paclitaxel plus carboplatin or three (3) treatment cycles of Taxoprexin® plus carboplatin, refusal of continued treatment by the patient, or Investigator decision.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have a histologic or cytologic diagnosis of non-small cell lung cancer. At the time of study entry, patients must have locally advanced (stage IIIb) or metastatic (stage IV) disease.
  2. Patients must have at least one site of either measurable or non-measurable disease.
  3. Patients must not have received prior systemic chemotherapy for metastatic disease. Prior adjuvant systemic chemotherapy is allowed. At least six (6) months must have elapsed since any prior adjuvant systemic chemotherapy.
  4. At least 6 weeks (42 days) since any prior immunotherapy, cytokine, biologic, vaccine or other non chemotherapy anticancer systemic therapies, unless patients have progressed during or after such therapy.
  5. At least 4 weeks (28 days) since any prior radiotherapy to > 25% of the bone marrow.
  6. Patients must have ECOG performance status of 0 - 2.
  7. Patients must be at least 18 years of age.
  8. Patients must have adequate hepatic and renal function.
  9. Patients must have adequate bone marrow function.
  10. Life expectancy of at least 3 months.
  11. Patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of their institution.

Exclusion Criteria:

  1. Patients who have received prior systemic chemotherapy in the adjuvant setting with a treatment-free interval of less than six (6) months.
  2. Patients who have a past or current history of neoplasms other than the entry diagnosis, except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix and except for other cancers treated for cure and with a disease-free survival greater than 5 years.
  3. Patients with symptomatic brain metastasis(es).
  4. Women who are pregnant or nursing and men or women who are not practicing an acceptable method of birth control. Women may not breast-feed while on this study.
  5. Patients with current active infections requiring anti-infectious treatment (e.g., antibiotics, antivirals, or antifungals).
  6. Patients with current peripheral neuropathy of any etiology that is greater than grade 1.
  7. Patients with unstable or serious concurrent medical conditions.
  8. Patients with a known hypersensitivity to Cremophor.
  9. Patients with Gilbert's syndrome.
  10. Patients must not have had major surgery within the past 14 days.
  11. Patients must not receive any concurrent chemotherapy, radiotherapy, or immunotherapy while on study.
  12. No known HIV disease or infection.
  13. Patients receiving ketoconazole, erythromycin, verapamil, diazepam, quinidine, or diltiazem.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00243867

United States, Texas
US Oncology
Dallas, Texas, United States, 75201
Sponsors and Collaborators
Luitpold Pharmaceuticals
Study Director: Robert Bellet, MD Luitpold Pharmaceuticals
  More Information

Responsible Party: Luitpold Pharmaceuticals Identifier: NCT00243867     History of Changes
Other Study ID Numbers: P01-04-20
Study First Received: October 21, 2005
Last Updated: July 22, 2015

Keywords provided by Luitpold Pharmaceuticals:
Advanced Non-Small Cell Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on April 24, 2017